PD-1H/VISTA mediates immune evasion in acute myeloid leukemia

Tae Kon Kim,Xue Han,Qianni Hu,Esten N Vandsemb,Carly M Fielder,Junshik Hong,Kwang Woon Kim,Emily F Mason,R Skipper Plowman,Jun Wang,Qi Wang,Jian-Ping Zhang,Ti Badri,Miguel F Sanmamed,Linghua Zheng,Tianxiang Zhang,Jude Alawa,Sang Won Lee,Amer M Zeidan,Stephanie Halene,Manoj M Pillai,Namrata S Chandhok,Jun Lu,Mina L Xu,Steven D Gore,Lieping Chen

DOI: https://doi.org/10.1172/JCI164325

2024-02-01

Abstract:Acute myeloid leukemia (AML) presents a pressing medical need in that it is largely resistant to standard chemotherapy as well as modern therapeutics, such as targeted therapy and immunotherapy, including anti-programmed cell death protein (anti-PD) therapy. We demonstrate that programmed death-1 homolog (PD-1H), an immune coinhibitory molecule, is highly expressed in blasts from the bone marrow of AML patients, while normal myeloid cell subsets and T cells express PD-1H. In studies employing syngeneic and humanized AML mouse models, overexpression of PD-1H promoted the growth of AML cells, mainly by evading T cell-mediated immune responses. Importantly, ablation of AML cell-surface PD-1H by antibody blockade or genetic knockout significantly inhibited AML progression by promoting T cell activity. In addition, the genetic deletion of PD-1H from host normal myeloid cells inhibited AML progression, and the combination of PD-1H blockade with anti-PD therapy conferred a synergistic antileukemia effect. Our findings provide the basis for PD-1H as a potential therapeutic target for treating human AML.